Search

everythinglearnresearchcommunity

for

Search:↓

Fluridil's effectiveness and safety in treating hair loss are discussed, with higher concentrations showing potential success. Comparisons are made to other treatments like RU58841, Pyri, CB-03-01, and topical spironalactone.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks upcoming Fluridil group buys.

The conversation discusses hair regrowth after a health condition, with the appearance of white substance on the scalp. Suggestions include it being sebum or White Piedra, with a recommendation to try Nizoral.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

Combining minoxidil 5%, tazarotene 0.1% cream, and lumigan for hair loss treatment is discussed. The conversation focuses on the safety and effectiveness of using these treatments together.

Oral Minoxidil can cause puffy eyes and fluid retention. Adding an ACE inhibitor or ARB, like Telmisartan, may help mitigate these side effects.

The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.

The user experienced reduced hair shedding after three months of injecting 1mg BPC-157 into the scalp, while continuing to use dutasteride and minoxidil. The injections are painful, and the user sometimes switches to injecting into the buttocks.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

A user's six month progress with Pyrilutamide, a hair loss treatment; they experienced positive results such as stopped itching and shedding, as well as regrowth, without any side effects.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

A user is excited to start using Pyriltamide for hair loss after experiencing side effects from topical finasteride. Other users discuss the potential and skepticism of Pyriltamide compared to older treatments like finasteride and RU58841.

A user created oral minoxidil sugar cubes due to lack of prescription access, leading to a humorous discussion about unconventional and potentially unsafe methods of using minoxidil. The conversation highlights the lengths people go to for hair growth.

The post discusses issues with Minoxidil BAILLEUL 5% Men, specifically sprayer clogging and crystallization in bottles. Recommendations include rinsing the sprayer and soaking the bottle in hot water to dissolve crystals, with calculations suggesting the product remains effective despite these issues.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

A user is starting a topical finasteride treatment for diffuse patterned alopecia, having previously used minoxidil without success. They are cautious about side effects and have chosen topical over oral finasteride, while also using Nizoral and biotin in their routine.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

The conversation is a humorous discussion about excessive hair growth due to using minoxidil, with suggestions of laser hair removal and comments on the appearance of the hair. Some users joke about starting finasteride treatment at a young age or being non-responders to hair loss treatments.

The user experienced prolonged hair shedding after restarting oral minoxidil (OM) at 2.5 mg in September 2023, following a break due to hypertrichosis. Despite seeing regrowth, the shedding has not decreased after 11 weeks on the increased dosage.

The conversation discusses using Bimatoprost for eyebrow regrowth and its potential use on the hairline, with concerns about cost and side effects. Alternatives like topical Minoxidil are mentioned, but the user is worried about aging and acne.

A user experienced severe side effects from using topical minoxidil sublingually, including muscle cramps, dizziness, and high potassium levels. They were advised to stop and seek medical help, emphasizing that topical minoxidil is not safe for ingestion due to its alcohol content.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.